Stock NAMS NEWAMSTERDAM PHARMA COMPANY N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus NewAmsterdam Pharma Company N.V. Nasdaq

Equities

NAMS

NL00150012L7

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-28 EDT 		5-day change 1st Jan Change
19.21 USD -1.69% Intraday chart for NewAmsterdam Pharma Company N.V. +6.60% +71.98%
06-11 NewAmsterdam Pharma Gets Another US Patent Extending IP Protection for Obicetrapib Until July 2043 MT
06-10 Transcript : NewAmsterdam Pharma Company N.V. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM

Evolution of the average Target Price on NewAmsterdam Pharma Company N.V.

Price target over the last 5 years

History of analyst recommendation changes

358.Qkq-DgF7A097ChpHi0dKnNWENazjAEv-pv-csiNA6Ec.KxLrZ08zViU9OnYg_wEv3ZrmWJyyWS6a0M7OwHsL2nEJH-9URRVNEA1hbQ~88050b1ad98a82609bd5b219b1980ce2

Analyst Recommendations on NewAmsterdam Pharma Company N.V.

TD Cowen Starts NewAmsterdam Pharma With Buy Rating MT
Scotiabank Starts NewAmsterdam Pharma With Sector Outperform Rating, $35 Price Target MT
RBC Raises Price Target on NewAmsterdam Pharma to $31 From $25, Keeps Outperform, Speculative Risk MT
Guggenheim Starts NewAmsterdam Pharma With Buy Rating, $30 Price Target MT
RBC Initiates NewAmsterdam Pharma at Outperform With Speculative Risk Qualifier, $25 Price Target MT
Credit Suisse Lifts NewAmsterdam Pharma's Price Target to $22 From $21, Keeps Outperform Rating MT
Credit Suisse Starts NewAmsterdam Pharma at Outperform With $21 Price Target MT
SVB Securities Initiates Coverage on NewAmsterdam Pharma With Outperform Rating, $19 Price Target MT
SVB Securities Starts NewAmsterdam Pharma at Outperform With $19 Price Target MT
William Blair Starts NewAmsterdam Pharma at Outperform MT
Jefferies Starts NewAmsterdam Pharma at Buy With $24 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
17.93 EUR
Average target price
35.19 EUR
Spread / Average Target
+96.28%
High Price Target
46.62 EUR
Spread / Highest target
+160.00%
Low Price Target
27.86 EUR
Spread / Lowest Target
+55.37%

Consensus detail

Consensus revision (last 18 months)

Analysts covering NewAmsterdam Pharma Company N.V.

TD Cowen
Scotiabank
RBC Capital Markets
Guggenheim
Credit Suisse
SVB Securities LLC
Jefferies & Co.
William Blair & Co.

Ratings for NewAmsterdam Pharma Company N.V.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. NAMS Stock
  4. NAMS Stock
  5. Consensus NewAmsterdam Pharma Company N.V.